Literature DB >> 24503087

Protection of non-human primates against rabies with an adenovirus recombinant vaccine.

Z Q Xiang1, L Greenberg2, H C Ertl3, C E Rupprecht4.   

Abstract

Rabies remains a major neglected global zoonosis. New vaccine strategies are needed for human rabies prophylaxis. A single intramuscular immunization with a moderate dose of an experimental chimpanzee adenovirus (Ad) vector serotype SAd-V24, also termed AdC68, expressing the rabies virus glycoprotein, resulted in sustained titers of rabies virus neutralizing antibodies and protection against a lethal rabies virus challenge infection in a non-human primate model. Taken together, these data demonstrate the safety, immunogenicity, and efficacy of the recombinant Ad-rabies vector for further consideration in human clinical trials.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Adenoviral vaccine; NHP; Rabies virus; VNA

Mesh：

Substances：

Year:  2014        PMID： 24503087      PMCID： PMC4038128          DOI： 10.1016/j.virol.2013.12.029

Source DB:  PubMed          Journal:  Virology        ISSN： 0042-6822            Impact factor:   3.616


  23 in total

1.  Adenovirus-based vaccines: comparison of vectors from three species of adenoviridae.

Authors:  H Chen; Z Q Xiang; Y Li; R K Kurupati; B Jia; A Bian; D M Zhou; N Hutnick; S Yuan; C Gray; J Serwanga; B Auma; P Kaleebu; X Zhou; M R Betts; H C J Ertl
Journal:  J Virol       Date:  2010-08-04       Impact factor: 5.103

2.  Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity.

Authors:  Diane M Roberts; Anjali Nanda; Menzo J E Havenga; Peter Abbink; Diana M Lynch; Bonnie A Ewald; Jinyan Liu; Anna R Thorner; Patricia E Swanson; Darci A Gorgone; Michelle A Lifton; Angelique A C Lemckert; Lennart Holterman; Bing Chen; Athmanundh Dilraj; Angela Carville; Keith G Mansfield; Jaap Goudsmit; Dan H Barouch
Journal:  Nature       Date:  2006-04-16       Impact factor: 49.962

3.  Duration of immunity: an anamnestic response 14 years after rabies vaccination with purified chick embryo cell rabies vaccine.

Authors:  Claudius Malerczyk; Deborah J Briggs; David W Dreesen; Angelika Banzhoff
Journal:  J Travel Med       Date:  2007 Jan-Feb       Impact factor: 8.490

4.  Survival of neutralizing antibody in previously rabies vaccinated subjects: a prospective study showing long lasting immunity.

Authors:  K Suwansrinon; H Wilde; M Benjavongkulchai; U Banjongkasaena; S Lertjarutorn; S Boonchang; R Suttisri; P Khowplod; S Daviratanasilpa; V Sitprija
Journal:  Vaccine       Date:  2006-02-28       Impact factor: 3.641

5.  Therapy of rabies encephalitis.

Authors:  Alan C Jackson
Journal:  Biomedica       Date:  2009-06       Impact factor: 0.935

Review 6.  The immune response to rabies virus infection and vaccination.

Authors:  Nicholas Johnson; Adam F Cunningham; Anthony R Fooks
Journal:  Vaccine       Date:  2010-04-03       Impact factor: 3.641

7.  Adenovirus-specific human T cells are pervasive, polyfunctional, and cross-reactive.

Authors:  Natalie A Hutnick; Diane Carnathan; Korey Demers; George Makedonas; Hildegund C J Ertl; Michael R Betts
Journal:  Vaccine       Date:  2010-02-23       Impact factor: 3.641

8.  Safety and immunogenicity of adenovirus-vectored near-consensus HIV type 1 clade B gag vaccines in healthy adults.

Authors:  Clayton D Harro; Michael N Robertson; Michelle A Lally; Lori D O'Neill; Srilatha Edupuganti; Paul A Goepfert; Mark J Mulligan; Frances H Priddy; Sheri A Dubey; Lisa S Kierstead; Xiao Sun; Danilo R Casimiro; Mark J DiNubile; John W Shiver; Randi Y Leavitt; Devan V Mehrotra
Journal:  AIDS Res Hum Retroviruses       Date:  2009-01       Impact factor: 2.205

9.  HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis.

Authors:  M Juliana McElrath; Stephen C De Rosa; Zoe Moodie; Sheri Dubey; Lisa Kierstead; Holly Janes; Olivier D Defawe; Donald K Carter; John Hural; Rama Akondy; Susan P Buchbinder; Michael N Robertson; Devan V Mehrotra; Steven G Self; Lawrence Corey; John W Shiver; Danilo R Casimiro
Journal:  Lancet       Date:  2008-11-13       Impact factor: 79.321

10.  Effect of preexisting immunity to adenovirus human serotype 5 antigens on the immune responses of nonhuman primates to vaccine regimens based on human- or chimpanzee-derived adenovirus vectors.

Authors:  Kimberly McCoy; Nia Tatsis; Birgit Korioth-Schmitz; Marcio O Lasaro; Scott E Hensley; Shih-Wen Lin; Yan Li; Wynetta Giles-Davis; Ann Cun; Dongming Zhou; Zhiquan Xiang; Norman L Letvin; Hildegund C J Ertl
Journal:  J Virol       Date:  2007-04-11       Impact factor: 5.103
View more
  14 in total

1.  A Partial E3 Deletion in Replication-Defective Adenoviral Vectors Allows for Stable Expression of Potentially Toxic Transgene Products.

Authors:  Larissa H Haut; Amanda L Gill; Raj K Kurupati; Ang Bian; Yan Li; Wynetta Giles-Davis; Zhiquan Xiang; Xiang Yang Zhou; Hildegund C J Ertl
Journal:  Hum Gene Ther Methods       Date:  2016-09-07       Impact factor: 2.396

2.  Construction and evaluation of novel rhesus monkey adenovirus vaccine vectors.

Authors:  Peter Abbink; Lori F Maxfield; David Ng'ang'a; Erica N Borducchi; M Justin Iampietro; Christine A Bricault; Jeffrey E Teigler; Stephen Blackmore; Lily Parenteau; Kshitij Wagh; Scott A Handley; Guoyan Zhao; Herbert W Virgin; Bette Korber; Dan H Barouch
Journal:  J Virol       Date:  2014-11-19       Impact factor: 5.103

3.  T cell responses to adenoviral vectors expressing the SARS-CoV-2 nucleoprotein.

Authors:  Mohadeseh Hasanpourghadi; Mikhail Novikov; Robert Ambrose; Arezki Chekaoui; Dakota Newman; Xiang Yang Zhou; Hildegund C J Ertl
Journal:  Curr Trends Microbiol       Date:  2021

Review 4.  Adenoviral vector-based strategies against infectious disease and cancer.

Authors:  Chao Zhang; Dongming Zhou
Journal:  Hum Vaccin Immunother       Date:  2016-04-22       Impact factor: 3.452

Review 5.  Rabies Control and Treatment: From Prophylaxis to Strategies with Curative Potential.

Authors:  Shimao Zhu; Caiping Guo
Journal:  Viruses       Date:  2016-10-28       Impact factor: 5.048

Review 6.  Lyssaviruses and rabies: current conundrums, concerns, contradictions and controversies.

Authors:  Charles Rupprecht; Ivan Kuzmin; Francois Meslin
Journal:  F1000Res       Date:  2017-02-23

7.  A next generation vaccine against human rabies based on a single dose of a chimpanzee adenovirus vector serotype C.

Authors:  Federico Napolitano; Rossella Merone; Adele Abbate; Virginia Ammendola; Emma Horncastle; Francesca Lanzaro; Marialuisa Esposito; Alessandra Maria Contino; Roberta Sbrocchi; Andrea Sommella; Joshua D Duncan; Jospeh Hinds; Richard A Urbanowicz; Armin Lahm; Stefano Colloca; Antonella Folgori; Jonathan K Ball; Alfredo Nicosia; Benjamin Wizel; Stefania Capone; Alessandra Vitelli
Journal:  PLoS Negl Trop Dis       Date:  2020-07-15

Review 8.  New human rabies vaccines in the pipeline.

Authors:  Anthony R Fooks; Ashley C Banyard; Hildegund C J Ertl
Journal:  Vaccine       Date:  2018-08-25       Impact factor: 3.641

Review 9.  Pre-existing immunity against Ad vectors: humoral, cellular, and innate response, what's important?.

Authors:  Hugues Fausther-Bovendo; Gary P Kobinger
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

10.  A simian-adenovirus-vectored rabies vaccine suitable for thermostabilisation and clinical development for low-cost single-dose pre-exposure prophylaxis.

Authors:  Chuan Wang; Pawan Dulal; Xiangyang Zhou; Zhiquan Xiang; Hooman Goharriz; Ashley Banyard; Nicky Green; Livia Brunner; Roland Ventura; Nicolas Collin; Simon J Draper; Adrian V S Hill; Rebecca Ashfield; Anthony R Fooks; Hildegund C Ertl; Alexander D Douglas
Journal:  PLoS Negl Trop Dis       Date:  2018-10-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.